期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

白细胞介素-6诱导CD44+ CD24-/low肿瘤干细胞生成促进乳腺癌MCF7细胞辐射抵抗的研究 被引量：2

Interleukin-6 promotesradiation resistance of breast cancer MCF7 cellsby induction of CD44+ CD24-/low cancer stem cells
下载PDF
导出
摘要 目的：上皮-间充质转化（EMT）能诱导 CD44＋CD24－／low乳腺癌干细胞的产生，白细胞介素-6（IL-6）是很强的 EMT 诱导因子，探讨 IL-6是否通过诱导 CD44＋CD24－／low细胞的产生，从而促进乳腺癌 MCF7细胞的辐射抵抗。方法含50 ng／ml IL-6的培养基培养 MCF7细胞，流式细胞术检测 CD44＋CD24－／low乳腺癌干细胞标记的变化，实时定量聚合酶链反应（Real-time PCR）及Western blot 检测 EMT 标记分子的表达水平，进一步利用流式细胞术从诱导组中分选出 CD44＋CD24－／low细胞，克隆形成实验检测分选后细胞的辐射抵抗能力。结果IL-6能诱导 MCF7细胞发生间充质样转化，诱导5 d 后 CD44＋CD24－／low细胞显著富集，诱导形成的 CD44＋CD24－／low细胞的辐射抵抗能力显著提高。结论IL-6诱导了 CD44＋CD24－／low 乳腺癌干细胞的产生，从而促进MCF7细胞的辐射抵抗。 Objective To determine whether interleukin-6（IL-6）,a welly established potent in-ducer of epithelial-mesenchymal transition（EMT）,promotes radiation resistance of breast cancer MCF7 cellsby induction of CD44 ＋CD24 -/low cancer stem cells Methods Breast cancer MCF-7 cells were cul-tured in 1 0% FBS DMEMwith 50 ng/ml IL-6.The percentages of CD44 ＋CD24 -/low cells were measured by flow cytometry.Real-time RT-PCR and western blotting were used to determine expression of markers associated with EMT.The capacity of radiation resistance was tested by colony formation.Results IL-6 induced EMT of MCF7 cells.CD44 ＋CD24 -/low cells were enriched after 5-day induction of IL-6 and these induced cells exhibited enhancedradiation resistance.Conclusion IL-6 induced the generation of CD44 ＋CD24 -/low cells and promoted radiation resistance in breast cancer MCF7 cells.
作者 郭昭泽 刘民锋 詹军芳 谢国柱 叶长生
机构地区 南方医科大学南方医院乳腺科
出处 《临床外科杂志》 2015年第6期431-434,共4页 Journal of Clinical Surgery
基金 国家自然科学基金资助项目(81302326)
关键词 白细胞介素-6 上皮-间充质转化 干细胞 辐射抵抗 interleukin-6 epithelial-mesenehymal transition stem cells radiation re-sistance
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献12

  • 1A1-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identifi- cation of tumorigenic breast cancer cells [ J ]. Proc Natl Acad Sci USA, 2003,100 ( 7 ) : 3983-3988.
  • 2AI-Hajj M, Becker MW, Wicha M, et al. Therapeutic implications of cancer stem cells [ J ]. Curr Opin Genet Dev,2004,14 ( 1 ) :43-47.
  • 3Hodge DR, Hurt EM, Farrar WL. The role of IL-6 and STAT3 in in- flammation and cancer [ J ]. Eur J Cancer, 2005,41 ( 16 ) : 2502 -2512.
  • 4Rose-John S, Scheller J, Elson G, et al. Interleukin-6 biology is coordi- nated by membrane-bound and soluble receptors:role in inflammation and cancer [ J ]. J Leukoe Biol,2006,80 ( 2 ) : 227 -236.
  • 5Knupfer H, Preiss R. Significance of interleukin-6 ( IL-6 ) in breast cancer(review) [ J ]. Breast Cancer Res Treat, 2007,102 ( 2 ) : 129- 135.
  • 6Baehelot T, Ray-Coquard I, Menetrier-Caux C, et al. Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vas- cular endothelial growth factor in hormone-refractory metastatic breast cancer patients[ J]. Br J Cancer,2003,88 ( 11 ) : 1721-1726.
  • 7Asgeirsson KS, Olafsdottir K, Jonasson JG, et al. The effects of IL-6 on cell adhesion and e-cadherin expression in breast cancer [ J ]. Cyto-kine, 1998,10 (9) :720-728.
  • 8Conze D, Weiss L, Regen PS, et all. Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells [ J ]. Cancer Res, 2001,61 (24) :8851-8858.
  • 9Sullivan NJ, Sasser AK, Axel AE, et al. Interleukin-6 induces an epi- thelial-mesenchymal transition phenotype in human breast cancer cells [ J]. Oneogene ,2009,28 ( 33 ) :2940-2947.
  • 10Morel AP, Lievre M, Thomas C, et al. Generation of breast cancer stem cells through epithelial-mesenchymal transition [ J ]. PLoS One, 2008, 3(8) :e2888.

同被引文献42

  • 1Bourguignon LY, Peyrollier K, Xia W, et al. Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells. J Biol Chem. 2008; 283(25): 17635-17651.
  • 2Yang J, Lam DH, Goh SS, et al. Tumor tropism of intravenously injected human-induced pluripotent stem cell-derived neural stem cells and their gene therapy application in a metastatic breast cancer model. Stem Cells. 2012;30(5): 1021-1029.
  • 3DevapaUa B, Sanders J, Samuelson DJ. Genetically determined inflammatory-response related cytokine and chemokine transcript profiles between mammary carcinoma resistant and susceptible rat strains. Cytokine. 2012;59(2):223-227.
  • 4Lee Y J, Galoforo SS, Berns CM, et al. Glucose deprivation-induced cytotoxicity and alterations in mitogen-activated protein kinase activation are mediated by oxidative stress in multidrug-resistant human breast carcinoma cells. J Biol Chem. 1998; 273(9):5294-5299.
  • 5Manuvakhova M, Thottassery JV, Hays S, et al. Expression of the SNT-1/FRS2 phosphotyrosine binding domain inhibits activation of MAP kinase and PI3-kinase pathways and antiestrogen resistant growth induced by FGF-1 in human breast carcinoma cells. Oncogene. 2006;25(44):6003-6014.
  • 6Ferguson P J, Brisson AR, Koropatnick J, et al. Enhancement of cytotoxicity of natural product drugs against multidrug resistant variant cell lines of human head and neck squamous cell carcinoma and breast carcinoma by tesmilifene. Cancer Lett. 2009; 274(2): 279-289.
  • 7Lee SA, Jung M. The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation. J Biol Chem. 2007; 282(20) 15271- 15783.
  • 8Heimberger AB, Sampson JH. The PEPvlII-KLH (CDX-110) vaccine in glioblastoma multiforme patients. Expert Opin Biol Ther. 2009;9(8): 1087-1098.
  • 9Wang KH, Kao AP, Lin TC, et al. Promotion of epithelial-mesenchymal transition and tumor growth by 17β-estradiol in an ER(+)IHER2(+) cell line derived from human breast epithelial stem cells. Biotechnol Appl Biochem. 2042;59(3):262-267.
  • 10Talukdar S, Kundu SC. Engineered 3D Silk-Based Metastasis Models: Interactions Between Human Breast Adenocarcinoma, Mesenchymal Stem Cells and Osteoblast-Like Cells.Advanced functional materials.2013;23(42):5249-5260.

引证文献2

二级引证文献11

临床外科杂志
2015年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部